In a market dominated by Big Pharma, small biotech companies have transformed the creation of new medicines, creating nearly 40 percent more of the most crucial medical treatments — and doing so on a budget. How has this been possible? In From Breakthrough to Blockbuster: The Business of Biotechnology (Oxford University Press), Drakeman, Drakeman, and Oraiopoulos show how biotech companies have beaten the odds to invent novel medicines with unprecedented efficiency.
